Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price target hoisted by equities researchers at Morgan Stanley from $123.00 to $130.00 in a research note issued to investors on ...
Gilead Sciences, Inc.'s ( NASDAQ:GILD ) recent soft profit numbers didn't appear to worry shareholders, as the ...
Gilead Sciences (NASDAQ:GILD – Free Report) had its price target raised by Oppenheimer from $115.00 to $132.00 in a report ...
FOSTER CITY, Calif., February 24, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Medicines Agency (EMA) has validated for parallel accelerated review the company’s ...
To manage risk, investors should diversify their stock portfolio across industries and this could be the stock to study in the pharmaceutical sector for the long haul.
Zacks Investment Research on MSN8d
3 Healthcare Stocks With Strong EPS Growth Potential to Buy in 2025The healthcare sector continues to advance with technological breakthroughs and growing demand for medical services, creating ...
Gilead Sciences, Inc. GILD reported better-than-expected fourth-quarter results and provided an upbeat guidance for 2025. Adjusted earnings per share (EPS) of $1.90 beat the Zacks Consensus ...
Our calculations are based on comprehensive, delayed quotes. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all ...
Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback